On November 24, 2020 Pierre Fabre reported that The National Institute for Health and Care Excellence (NICE) has back Braftovi plus cetuximab for the treatment of BRAF-positive metastatic colorectal cancer (Press release, PharmaTimes, NOV 24, 2020, View Source [SID1234571775]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In September, NICE initially turned down Braftovi (encorafenib) after finding that the cost-effectiveness estimates were higher than what is normally considered value for money for the NHS.

However, NICE has now decided to recommend the drug in combination with cetuximab for BRAF V600E mutation-positive metastatic colorectal cancer (mCRC) in adults who have had previous systemic treatment.

The NICE decision is based on results from the phase III BEACON CRC trial, which showed that Braftovi plus cetuximab significantly improved median overall survival in patients with BRAF V600E-mutated mCRC and reduced the risk of death by 39%.

The combination treatment also produced an improved objective response rate compared to the control arm.

"We are delighted that NICE has recognised the value of Braftovi plus cetuximab for this high medical-need population," said Laura McMullin, general manager UK & Ireland, Pierre Fabre.

"Securing NHS reimbursement is the culmination of collaborative discussions that we have been having with NICE and NHS England since the end of last year.

"In particular, we would like to recognise the efforts of NHS England who have consistently supported appropriate access for this treatment. The result underscores our commitment to the colorectal cancer community and we hope that as many people as possible will benefit from this innovative treatment," she added.

On November 24, 2020 Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, reported that management will present at two upcoming virtual investor conferences in December (Press release, Protara Therapeutics, NOV 24, 2020, View Source [SID1234573139]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Piper Sandler 32nd Annual Virtual Healthcare Conference
Evercore ISI 3rd Annual HealthCONx Virtual Conference on Thursday, December 3, 2020 at 12:10pm ET
A webcast of the live Evercore presentation can be accessed by visiting the Events and Presentations section of the Company’s website: View Source A replay of the pre-recorded Piper fireside chat is currently available on the Company’s website. The webcasts will be archived on the Company’s website for 90 days following the presentation.

On November 24, 2020 the Spanish start-up, specialized in developing a technology to transport drugs to the brain, reported the company is seeking up to three million euros to reach the clinical trial (Press release, Gate2Brain, NOV 24, 2020, View Source [SID1234641077]). The CEO of Gate2Brain, Meritxell Teixidó, explains to PlantaDoce that the company plans to open a financing round in April 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The start-up develops a technology to transport drugs to the brain . The company will use the funds to advance therapeutic tests since, although it has identified the drug to deliver to this organ according to the group of pediatric brain tumors, it must improve transport.

In this way, the company would increase the effectiveness of brain disease treatments with its technology, while reducing side effects. Teixidó assures that the objective is "to validate the platform and for a pharmaceutical company to look at it to acquire the company . "

Gate2Brain seeks to improve the effectiveness of brain disease treatments

The company is a spin off of the Barcelona Biomedical Research Institute, the University of Barcelona (UB) and the Sant Joan de Déu Research Institute of the Sant Joan de Déu Hospital (SJD). The company has its headquarters in the Barcelona Science Park.

Gate2Brain envisions its technology will allow drugmakers to recover promising drugs that don’t make it to market because they can’t be transported to the brain. The company’s CEO states that "98% of drug candidates are discarded because they do not pass the barrier and our technology would allow investment in these drugs not to be left in a corner." The company is in contact with some pharmaceutical companies .

The start-up plans to open a financing round of between two million euros and three million euros in April 2021 . Gate2Brain estimates to begin the clinical trial in 2023. The company has carried out some tests at the Sant Joan de Déu Hospital in Barcelona and has observed that its technology would have applicability in various tumors.

Gate2Brain has received funding from the Botín Foundation

Gate2Brain has received support from the Botín Foundation’s Mind The Gap Program, which invests up to half a million euros per project . The start-up obtained online research support from the CaixaImpulse program of the La Caixa Foundation and funding from the Agency for Management and University Research Grants (Agaur) in the Knowledge Industry Grants call.

The company currently has five workers. Gate2Brain, founded by Teixidó and three other entrepreneurs, has Marc Ramis, CEO of Ninevah Therapeutics, as an advisor. The founders control the majority of the company’s shareholders.

On November 24, 2020 Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, reported that members of the Alpine senior leadership team will participate in an analyst-led fireside chat at the Evercore ISI 3rd Annual HealthCONx Virtual Conference on Thursday, December 3, 2020, at 4:45 p.m. ET/1:45 p.m. PT (Press release, Alpine Immune Sciences, NOV 24, 2020, View Source [SID1234571655]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available online in the investor relations section of the company’s website at View Source A replay of the presentation will be available on the company website for 90 days following the webcast.

On November 24, 2020 Repertoire Immune Medicines, a clinical-stage biotech company creating a new category of immune therapies for cancer, autoimmune and infectious disease, reported that it will present at the 32nd Annual Piper Sandler Virtual Healthcare Conference on Monday, November 30, 2020 (Press release, Repertoire, NOV 24, 2020, View Source [SID1234571677]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!